Patients With Gout Likely To Develop CKD, Kidney Stones
the Clinical Pain Advisor take:
Gout may predispose patients to chronic kidney disease (CKD) and nephrolithiasis, suggests a new meta-analysis published in Arthritis Research and Therapy.
Investigators pooled results from 17 epidemiological studies of gout patients. Estimates of CKD (stage 3 and above) and nephrolithiasis among people with gout were 24% and 14%, respectively.
In addition, gout was linked with more than twice the odds of developing CKD and one and a half times the odds of ever developing nephrolithiasis. Few of the included studies were prospective, so the researchers couldn't assess timing.
According to the researchers, patients with gout should actively be screened for CKD and its related conditions. Currently, just 1 in 5 patients with acute gout are screened for CKD within a month of presentation.
There are several possible mechanisms by which gout could lead to CKD and kidney stones, they noted. Kidney damage may result from hypertension, diabetes, nonsteroidal anti-inflammatory drugs, and endothelial dysfunction from hyperuricemia. Or, persistent inflammation from gout may cause vascular damage.
Treatment with allopurinol was believed to interfere with kidney function, but a recent systematic review suggested that it actually may protect against CKD progression.
Associations between gout and renal disease and nephrolithiasis have long been recognized.
Associations between gout and renal disease and nephrolithiasis have long been recognised, yet early studies undertaken in specialist secondary care populations are likely to be unrepresentative of most patients with gout who are managed exclusively in primary care settings. To the best of our knowledge, no previous systematic reviews examining this association have been performed.
Clinical Pain Advisor Articles
- Opioid Use in Chronic Low Back Pain: A Population Study
- Risks Associated With Co-Administration of Aspirin and Other NSAIDs
- Stages of Low Back Pain Have Specific Sets of Clinical Indicators
- FDA Approves Aimovig for Migraine Prevention
- First Non-Opioid Drug Approved for Managing Opioid Withdrawal Symptoms
- Effect of Prescription Drug Monitoring Programs on Fatal, Nonfatal Drug Overdoses
- Standardized SCS Workflow May Effectively Alleviate Failed Back Surgery Syndrome-Related Pain
- Marijuana Legalization and Opioid Prescribing Rates
- Medical Marijuana Users More Likely to Use Prescription Drugs for Medical, Nonmedical Purposes
- Interbrain Coupling During Handholding Associated With Analgesia, Empathy
- Opioid-Related Adverse Drug Events Associated With Worse Patient, Cost Outcomes
- Education Plus Exercise, Single Corticosteroid Injection Effective in Long Term for Gluteal Tendinopathy
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Naloxone Training Beneficial for PA Students
- Supervised Injection Sites Hailed as the Latest Strategy to Fight the Opioid Crisis